Prevalence of colonization and multilocus genotyping profiles of Pneumocystis jirovecii among patients with various pulmonary disorders in Poland

Authors: Hendrich AB, Kicia M, Kopacz Z, Kowal A, Lobo ML, Matos O, Piesiak P, Sokulska M, Wesolowska M
Publication Year: 2017
Journal: Medical Mycology

This study describes the prevalence and genotype distribution of Pneumocystis jirovecii obtained from nasopharyngeal (NP) swabs from immunocompetent Cuban infants and toddlers with whooping cough (WC). A total of 163 NP swabs from 163 young Cuban children with WC who were admitted to the respiratory care units at two pediatric centers were studied. The prevalence of the […]
Read More

Pneumocystis jirovecii pneumonia: Still a concern in patients with haematological malignancies and stem cell transplant recipients-authors’ response

Authors: de Sousa B, Lobo ML, Matos O, Patrocinio G, Sevivas T
Publication Year: 2017
Journal: Epidemiology & Infection
Link: https://www.cambridge.org/core/journals/epidemiology-and-infection/article/portugal-and-angola-similarities-and-differences-in-toxoplasma-gondii-seroprevalence-and-risk-factors-in-pregnant-women/8ABAD35CD7741CC84F21302DF0BD8531

In this study we determined the presence of IgM/IgG antibodies to Toxoplasma gondii in sera of 155 and 300 pregnant women from Lisbon (Portugal) and Luanda (Angola), respectively, and evaluated the potential risk factors associated with this infection. DNA detection was performed by PCR assays targeting T. gondii regions (RE/B1). Overall, 21·9% (10·9% IgG, 10·9% […]
Read More

High prevalence of Pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with a first episode of Pneumocystis pneumonia in Santiago, Chile, and clinical response to trimethoprim-sulfamethoxazole therapy

Authors: Bustamante R, Cárdenas A, Chabé M, Durán L, George C, Guerrero J, Huang L, Matos O, Miller RF, Ponce CA, Vargas SL
Publication Year: 2017
Journal: Antimicrobial Agents and Chemotherapy
Link: http://aac.asm.org/content/61/2/e01290-16

Mutations in the dihydropteroate synthase (DHPS) gene of Pneumocystis jirovecii are associated with the failure of sulfa prophylaxis. They can develop by selection in patients receiving sulfa drugs or be acquired via person-to-person transmission. DHPS mutations raise concern about the decreasing efficacy of sulfa drugs, the main available therapeutic tool for Pneumocystis pneumonia (PCP). The […]
Read More

Diversity of Pneumocystis jirovecii Across Europe: A Multicentre Observational Study

Authors: Alanio A, Bretagne S, Calderón EJ, Desnos-Ollivier M, Di Cave D, Dupont D, Gits-Muselli M, Guigue N, Hamprecht A, Hauser PM, Helweg-Larsen J, Kicia M, Lagrou K, Lengerova M, Matos O, Melchers WJG, Morio F, Nevez G, Totet A, White LP
Publication Year: 2017
Journal: EBioMedicine
Link: http://www.ebiomedicine.com/article/S2352-3964(17)30262-1/fulltext

Pneumocystis jirovecii is an airborne human-specific ascomycetous fungus responsible for Pneumocystis pneumonia (PCP) in immunocompromised patients, affecting >500,000 patients per year (www.gaffi.org). The understanding of its epidemiology is limited by the lack of standardised culture. Recent genotyping data suggests a limited genetic diversity of P. jirovecii. The objective of the study was to assess the […]
Read More

Prevalence of colonization and multilocus genotyping profiles of Pneumocystis jirovecii among patients with various pulmonary disorders in Poland

Pneumocystis jirovecii pneumonia: Still a concern in patients with haematological malignancies and stem cell transplant recipients-authors’ response

Portugal and Angola: Similarities and differences in Toxoplasma gondii seroprevalence and risk factors in pregnant women

High prevalence of Pneumocystis jirovecii dihydropteroate synthase gene mutations in patients with a first episode of Pneumocystis pneumonia in Santiago, Chile, and clinical response to trimethoprim-sulfamethoxazole therapy

Diversity of Pneumocystis jirovecii Across Europe: A Multicentre Observational Study

About GHTM

Contacts

Map